George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Came across that one this morning as well :)
Looks like it made reference to our own Med Hypotheses
"Platelet hyperactivity in COVID-19: can the tomato extract Fruitflow® be used as an antiplatelet regime?"
Hope this link works https://bit.ly/32Z3mxv
Google Scholar alert for Fruitflow flagged this paper today, published last week . All about platelets but unable to get free read of paper to see whether FF actually mentioned
https://www.tandfonline.com/doi/full/10.1080/09537104.2021.1961718
Coagulopathy is an evident complication of COVID-19 with predominance of a prothrombotic state. Platelet activation plays a key role. The terms “hyper-reactivity” and “hyperactivity” used in recent literature may not be clear or sufficient to explain the pathological events involved in COVID-related thrombosis (CRT). Inflammation may play a bigger role compared to thrombosis in COVID-related mortality because a smaller percentage of patients with COVID-19 die due to direct effects of thrombosis. Not all COVID-19 patients have thrombocytopenia and a few show thrombocytosis. We believe the platelet pathology is more complex than just activation or hyper-activation, particularly due to the platelets’ role in inflammation. Understanding the pathology and consequences of platelets’ role may help optimize management strategies and diminish CRT-associated morbidity and mortality. In this viewpoint report, we examine the published evidence of platelet hyper-reactivity in COVID-19 with a focused analysis of the key pathologies, diverse alterations, disease outcomes, and therapeutic targets. We believe that COVID-19 is a disease of inflammation and pathologic platelets, and based on the complexity and diverse pathologies, we propose the term “thrombocytopathy” as a more reflective term of the platelets’ involvement in COVID-19. In our opinion, thrombocytopathy is the unpredictable pathologic alterations of platelets in function, morphology and number, caused by different factors with a variety of presentations.
WS
I agree with you, but think that it won't be our choice. The big holders, and board, will have the choice.
We don’t want to be bought out, we want a hugely successful product and excellent profits.
gixer,
Many thanks for sharing the info. I like the following statement
statistically significant(P<0.001)
I was involved with some statistical modelling few years back.
statistically significant is something wonderful they achieved. It is matter of time BY Health is going to make an offer to buy us.
Our good friend IF should put all these links in PXS website.
Study on the Effect of Tomato Water-soluble Extract Xinluosu on Platelet Function and Its Molecular Mechanism.
Can't remember if this Chinese study has been posted before but also has quite a few references to PF4.
"The level of PF4 was also reduced after Fruitflow intervention,and the difference between before and after intervention was statistically significant(P<0.001)"
"Conclusions1.Fruitflow can inhibit platelet aggregation,reduce the production of TXB2,6-keto-PGF1aand the release of PF4 stimulated by ADP and Collagen."
"Fruitflow has certain application prospects and important scientific significance in the prevention of cardiovascular disease research."
https://dysw.cnki.net/kcms/detail/detail.aspx?filename=1021699508.nh&dbcode=CMFD&dbname=CMFDTEMP&v=
He did, yes.
Let's hope he includes the benefits of fruitflow on PF4 to cover this new discovery on why the vaccine causes blood clots.
gix/alf
thx.....
I recall the prof referring to an imminent paper on FF & CV during his recent AFC webinar. I don't think it's out there yet. ?
WS
This has been known for years. Keep up!
The problem has been/is that not enough people know about it.
Which may provide a novel evidence for the cardioprotective benefits of tomato.
WOW what a wonderful evidence. I take fruitflow daily and my blood pressure and heart rate are so normal. Now I know what is keeping all these normal.
gixer,
Many thanks for sharing your great find.
Conclusion: Fruitflow effectively inhibited platelet granule secretion via down-regulating platelet Src/PLC-?2/PKC signaling pathway in vitro , which may provide a novel evidence for the cardioprotective benefits of tomato.
It is definitely something good and waiting to explode. I will put some additional fund now before it explode in near future.
This other Chinese study also refers a lot to PF4
https://www.researchgate.net/publication/340194606_Fruitflow_attenuates_human_platelet_granule_secretion_through_down-regulating_SrcPLCg2PKC_signaling_pathway/fulltext/5e7ce5fd458515efa0ad6b2e/Fruitflow-attenuates-human-platelet-granule-secretion-through-down-regulating-Src-PLCg2-PKC-signaling-pathway.pdf
"Fruitflow inhibited platelet surface expression of CD62P, CD40L, and CD63. Moreover, agonist-induced release of platelet factor 4 (PF4)"
Can only be a good thing.
They definitely are aware, and active, in furthering this research. Clinical proof is a hard fought battle though, so nothing can be certain.
Lots in news: Covid: Trigger of rare blood clots with AstraZeneca jab found by scientists
https://www.bbc.co.uk/news/health-59418123
Seems to involve platelet factor 4. This study says FF suppresses PF4. Way beyond my paygrade to understand whether taking FF would be beneficial in reducing the risk. Can only assume IF/Felix/NK/Prof are on top of this !!
https://www.researchgate.net/publication/346593847_Inhibitory_effect_of_Fruitflow_on_platelet_function_a_randomized_placebo-controlled_trial_in_elderly_subjects
Fruitflow suppressed platelet aggregation and decreased TXB2, 6-keto-PGF1a, and PF4 levels in elderly subjects. These findings indicate that FF might reduce the risk of thrombosis in cardiovascular diseases. Trial registration code: ChiCTR2000034647 at www.clinicaltrials.gov.
W$
Why would anyone think that he doesn't already know?
Beats me.
Sorry but i think its IF's job to inform us,not the other way around.
No, nothing major found in the US.
gix
Anything out there from US ?
It all seems to be happening in India/Asia. Given it is the biggest market, it is disappointing it has been radio silence from the US. We have the patents but it seems little/no traction over there re products aside from Brickerlabs and Swanson that have been around for years.
W$
Hi gixer,
Great find. Wonderful detective work. If you have a contact e-mail address of our good friend IF please send all these links so that he could include all these great research in PXS website.
This is another.
"Effect of tomato, lycopene and related products on blood pressure: A systematic review and network meta-analysis"
"Subgroup analysis in hypertensive patients showed that STE significantly reduced both SBP and DBP with pooled MDs (95% CIs) of –8.09 (–11.52 to –4.67) and –4.25 (–6.97 to –1.53) mmHg, respectively, compared to placebo. Other forms of tomato, including other dose ranges of standardized tomato extract, tomato-containing diet, lycopene-free preparation, and synthetic lycopene, did not show consistent and significant effects on either SBP or DBP in all analyses.
Conclusion
Standardized tomato extract (STE) significantly decreased SBP compared to placebo in a mixed population of healthy volunteers and hypertensive patients. The BP-lowering effect was more pronounced among hypertensive patients. No significant BP effects were seen with other forms of tomato, lycopene and related products in the overall population or any subgroup of the population.
https://www.sciencedirect.com/science/article/abs/pii/S0944711321000544
Not just the Chinese that are doing studies.......
Fruitflow is included in this Pharmacological Research Review but unfortunately its a pay to view.
"The current use and evolving landscape of nutraceuticals"
https://www.sciencedirect.com/science/article/abs/pii/S1043661821005855#!
A google search brings up.....
The Current Use and Evolving Landscape of Nutraceuticalshttps://www.sciencedirect.com › science › article › pii
5 days ago — One such example of a successful product is Fruitflow® manufactured by Provexis. ... ScienceDirect ® is a registered trademark of Elsevier B.V..
"The "big health era" is coming,
that is a big balls brassy statement , didn't get one of those from DSM post EU13
As you can see, it was only set up in May last year.
https://www.ltddir.com/companies/byhealth-international-company-limited/
Top spot ? During this year's Double 11, BYHEALTH retained its top spot on Alibaba and JD’s VDS charts in China. Sales of RMB$600m (US$93.9m) were achieved, which was 38.3 per cent more than last year. “BYHEALTH International range has achieved amazing results as well, with about 200 per cent yoy growth in GMV as compared to last year’s Double 11,” ?she said. There are currently 10 to 15 SKUs in the BYHEALTH international range, with the products manufactured in the United States or Australia. These products are sold into China via cross-border e-commerce (CBEC) through Tmall, JD, and are also stocked in Chemist Warehouse outlets in China. Gu revealed that about 70 per cent of the international products sales came from China – making China a key focus at the moment. The remaining sales are from Hong Kong, Australia, New Zealand, and Singapore – which the brand only entered in August this year.? In contrast to China, the more popular products in Hong Kong are its collagen gummies and iron sachet powder.
NPD directions ? Gu said that BYHEALTH International would be exploring immune, cardiovascular, and men’s health as part of its new product development. “Interestingly, categories such as immune enhancement and cardiovascular protection have also increased by around 16 per cent in the past year,” ?she said. BYHEALTH recently entered into a partnership with UK company Provexis which has developed a proprietary heart health functional food ingredient known as Fruitflow. Under the agreement, BYHEALTH would manufacture, market, and sell functional food and dietary supplements containing the ingredient in Mainland China, Hong Kong, Macau, Taiwan, and Australia. The agreement will take full effect from Jan 1, 2023.
"Gu said that BYHEALTH International would be exploring immune, cardiovascular, and men’s health as part of its new product development."
FWIW "BYHEALTH International" is a Hong Kong registered company that appears to be for cross border products.
https://www.nutraingredients-asia.com/Article/2021/11/29/For-the-night-owl-BYHEALTH-reports-strong-sales-of-milk-thistle-melatonin-products-in-11.11?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright